Canadian Labelling For All Jak Inhibitors To Include Risks Of Serious Heart-related Problems, Fatal Blood Clots And Cancer

Health Canada is updating the labels on six JAK inhibitor medications (Cibinqo, Inrebic, Jakavi, Olumiant, Rinvoq, and Xeljanz/Xeljanz XR) to include warnings about serious risks including heart problems, blood clots that can be fatal, and cancer. This labelling change applies to all JAK inhibitors used across Canada. The update reflects new safety information about these drugs.

Product

Janus Kinase (JAK) inhibitors, including: Cibinqo, Inrebic, Jakavi, Olumiant, Rinvoq and Xeljanz/Xeljanz XR.

Reason

Labelling

Category

consumer product recall

Country

Canada

Agency

HC-PRODUCTS

Recall date

2022-11-01

Status

Ongoing

Distribution

Canada-wide

Official recall notice from HC-PRODUCTS

Recall details on Nibble Recalls: https://trynibble.app/recalls/79314049-db66-4bce-98f7-37e7256e9e37